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Treatment options for irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD)
are notoriously either inadequate (IBS) or loaded with potentially serious side effects and
risks (IBD). In recent years, a growing interest in effective and safer alternatives has focused
on the potential role of probiotics and their metabolic substrates, prebiotics. It is in fact
conceivable that the microbiome might be targeted by providing the metabolic fuel needed
for the growth and expansion of beneficial microorganisms (prebiotics) or by administering
to the host such microorganisms (probiotics). This review presents a concise update on
currently available data, with a special emphasis on children. Data for prebiotics in IBS are
scarce. Low doses have shown a beneficial effect, while high doses are counterproductive.
On the contrary, several controlled trials of probiotics have yielded encouraging results. A
meta-analysis including nine randomized clinical trials in children showed an improvement
in abdominal pain for Lactobacillus GG, Lactobacillus reuteri DSM 17938, and the probiotic
mixture VSL#3.The patients most benefiting from probiotics were those with predominant
diarrhea or with a post-infectious IBS. In IBD, the use of prebiotics has been tested only
rarely and in small scale clinical trials, with mixed results. As for probiotics, data in humans
from about three dozens clinical trials offer mixed outcomes. So far, none of the tested
probiotics has proven successful in Crohn’s disease, while in ulcerative colitis a recent
meta-analysis on 12 clinical trials (1 of them in children) showed efficacy for the probiotic
mixture VSL#3 in contributing to induce and to maintain remission. It is evident that this
is a rapidly evolving and promising field; more data are very likely to yield a better under-
standing on what strains should be used in different specific clinical settings and in what
doses.
Keywords: irritable bowel syndrome, functional gastrointestinal disorders, inflammatory bowel disease, probiotics,
VSL#3, Lactobacillus, Crohn’s disease, ulcerative colitis
INTRODUCTION
Irritable bowel syndrome (IBS) is a very common disorder, affect-
ing up to 20% of children and teenagers (1), equally involving
boys and girls (2) and causing an important health and social
burden and with substantial costs (3, 4). IBS is a functional gas-
trointestinal disorder (FGID) characterized by the association of
recurrent abdominal pain to a change in stool consistency or fre-
quency toward a diarrhea- or a constipation-predominant pattern.
Its treatment remains largely unsatisfactory.
Inflammatory bowel diseases (IBDs) are a group of chronic,
incurable inflammatory disorders of the gastrointestinal tract
[mostly represented by Crohn’s disease (CD) and ulcerative col-
itis]. Their cause is unknown, but genetic, immunologic, and
environmental factors are involved. The peak age of onset for IBD
is 15–30 years, but it may occur at any age. About 10% of cases
have their onset before the age of 18, with CD being more fre-
quent in girls, while ulcerative colitis is more common in boys (5).
The disease is one of the most prevalent gastrointestinal disease
burdens in Western societies and it has become more widespread;
its rise in incidence has been reported in all age groups including
early childhood (6).
Prebiotics (7) are carbohydrates that transit undigested through
the small intestine and eventually reach the colon where they
stimulate the growth and/or the activity of beneficial bacteria,
mostly bifidobacteria and lactic acid bacteria. Prebiotics include
galacto-oligosaccharides (GOS), fructo-oligosaccharides (FOS),
inulin, and β-glucan (8). The potential for their use in IBS and
IBD, in addition to their stimulatory effect on potential probi-
otic microorganisms, stems also from the observation that some
prebiotics (e.g., mannanoligosaccharides, inulin, or β-glucan), are
thought to be “immunosaccharides,” i.e., they might act as direct
stimulators of innate immunity (9).
Probiotics on the other hand are defined as “live microorgan-
isms that, when administered in adequate amounts, confer a health
benefit on the host” (10).
There is a conceivable benefit in their use in both, IBS and IBD.
In IBS, alterations in the gut microbiota composition have been
well described (reviewed in a recent report by the Rome working
team) (11) and recent evidence has elucidated the growing impor-
tance of the microbiota–gut–brain axis in the development of IBS
(12). As for IBD, the potential role for such compounds appears
logical: the endogenous intestinal microbiota plays a central role in
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the disease development, and various probiotics have been found
effective in a variety of animal models.
This review will examine the current status of the utilization of
probiotics and prebiotics in children for both disorders.
PROBIOTICS IN IBS
Irritable bowel syndrome is defined (13) by the association of
abdominal pain with a change in stool pattern in the absence of
an organic cause. It is a very prevalent FGID, affecting up to 50%
of the children and teenagers seen by a gastroenterology practice
(14, 15) and causing significant health care costs and a negative
impact on quality of life (16).
Changes in gastrointestinal motility, brain/gut interaction, low-
grade inflammation, psychosocial disturbance, visceral hypersen-
sitivity, and altered microbiota appear to contribute to various
extents to its onset (17, 18). It is also possible that IBS results from
different pathogenetic factors that contribute in various degrees
in different patients (19).
How could probiotics be useful in IBS? IBS appears often
to follow an episode of gastroenteritis (“post-infectious IBS”),
(20) and intestinal microbiota changes have been described in
patients with IBS (21–23); furthermore, it is quite conceivable that
microbiota may interfere with additional factors involved in the
pathophysiology of IBS (24, 25).
In adults, several trials have been published, mostly of a small
scale and bearing in general promising results (17, 26, 27).
In children, however, fewer randomized clinical trials (RCTs)
are available.
EFFECTS OF PROBIOTICS ON ABDOMINAL PAIN
We conducted a double-blinded, placebo-controlled, cross-over
RCT (28) examining the effect of the probiotic mixture VSL#3, a
proprietary preparation consisting of a high concentration of eight
different probiotic strains (Lactobacillus acidophilus, Lactobacillus
plantarum, Lactobacillus casei, Lactobacillus bulgaricus, Bifidobac-
terium breve,Bifidobacterium longum,Bifidobacterium infantis, and
Streptococcus thermophilus), in children and teenagers with IBS.
Our results showed that while the patients were taking VSL#3, they
experienced a significant (p< 0.05) improvement in the global
subjective relief of symptoms score as well as in the score for
abdominal pain/discomfort. Similarly, significant benefits were
found for bloating/gassiness and for caregivers’ satisfaction with
their child improvement, while no significant improvement was
seen for diarrhea or constipation.
In 2014, systematic review and meta-analysis (29) on the effect
of different probiotics as a treatment for FGID in children and
teenagers included nine trials, five of whom, including our trial
(28), focused on abdominal pain-related FGID (15, 28, 30–32),
and four on bowel changes-related FGID (33–36).
The meta-analysis concluded that the use of Lactobacillus GG,
Lactobacillus reuteri DSM 17938 and VSL#3 significantly increased
treatment success in children with abdominal pain-related FGID,
particularly those with associated bowel changes. Of interest, L.
reuteri DSM 17938’s significant decrease of abdominal pain inten-
sity persisted after the removal of the probiotic, indicating a lasting
effect of the supplementation (31).
EFFECTS OF PROBIOTICS ON FUNCTIONAL DIARRHEA OR
CONSTIPATION
Notably, the two RCTs that assessed the effect of probiotics (Lac-
tobacillus GG and VSL#3) on the parameter of diarrhea (15, 28)
did not show any benefit of the intervention.
Four studies included in the meta-analysis assessed
constipation-related FGID. The probiotics used were Lactobacillus
GG associated with lactulose, L. casei rhamnosus Lcr35, B. longum,
and Bifidobacterium lactis DN-173 010 (33–36). The results were
disappointing, with no evidence that probiotics are more effec-
tive than placebo in overall outcome of treatment or in increasing
defecation frequency in constipated children and with inconsistent
data on the improvement in stool consistency (34, 35).
PROBIOTICS IN IBD
It is now well established that intestinal microbiota play an impor-
tant role in IBD (37). Probiotics appear therefore as a logical option
to positively influence the clinical course of IBD. They possess
anti-inflammatory action and enhance the gut barrier, and since
the inflammation in IBD results from an altered mucosal immune
response to luminal bacterial antigens, the use of live microor-
ganisms may conceivably favorably affect the overall microbial
balance.
The mechanisms of action underlying the benefits of probi-
otics in IBD have been largely and quite extensively investigated
in a variety of in vitro and in vivo animal experiments [reviewed
in Ref. (38)]. It is thought that in general, the effects manifested
by a specific probiotic depend on its metabolic properties, the
molecules surface-expressed molecules, and the products they
secrete (39).
However, in spite of the strength of the conceptual basis for
the beneficial use of probiotics, and of the extensive experi-
mental data in animal models, the existing literature – and in
particularly RCTs – on the use of probiotics in IBD is relatively
limited. I will consider here only published studies reporting
RCTs with a comparator, either placebo or an accepted standard
therapy.
CROHN’S DISEASE
A meta-analysis on probiotics in adult IBD published in 2012 (40)
included eight papers in CD: four conducted in active CD (only
one of which placebo-controlled). The latter trial reported a lower
relapse rate after 12 months receiving of Escherichia coli Nissle
1917 added to prednisolone therapy (41). The other four studies
were conducted in patients with CD in remission: two used Lac-
tobacillus GG (42, 43) and two Lactobacillus johnsonii (44, 45). In
none of the studies were probiotics more effective than placebo in
preventing relapses.
A subsequent and recent meta-analysis (46) included 23
RCT (12 in UC, 4 in “pouchitis,” and 7 in CD, only 3 of
them in children) with a total of 1763 participants: again
results were quite disappointing, as in none of the trials in
CD probiotics appeared to be of any significant benefit. Focus-
ing on the three pediatric trials (41, 43, 47) where the remis-
sion/response rates in acute CD were reported, in none was any
positive effect of probiotics supplementation shown (p= 0.35,
RR= 0.89).
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Seven RCTs (including only one in children, reported in more
detail below) examined the frequency of and timing to clinical
relapses in CD patients who were in remission. Again, no differ-
ence was found between the probiotics-supplemented patients and
the control ones (p= 0.71, RR= 1.09).
In children,a randomized,placebo-controlled trial of the probi-
otic Lactobacillus GG (48) with the aim of comparing the remission
in patients that receive Lactobacillus GG added to standard ther-
apy was unable to demonstrate that this probiotic would prolong
remission time in patients with CD already in remission on stan-
dard therapy. In fact, the time to relapse and proportion of patients
relapsing was essentially identical in both Lactobacillus GG and
placebo groups.
ULCERATIVE COLITIS
Twelve of the 23 RCTs included in the 2014 meta-analysis (46)
were conducted in UC patients.
Nine studies analyzed the remission/response in acute UC, uti-
lizing bifidobacteria, E. coli Nissle 1917, and VSL#3, while the
overall analysis of these RCTs showed significant benefit from
the use of probiotics, the sub-analysis based on probiotic utilized
documented such significant effect only for VSL#3 (49–53).
Escherichia coli Nissle 1917 is one of the few probiotics licensed
as a medicine in Europe where it is utilized in patients with ulcer-
ative colitis; its genome has recently been characterized (54). In
spite of a promising open-label pilot trial in 34 children in 2008
(55), no further trial have been conducted in children. In adults,
the meta-analysis’ subgroup analysis (46) failed to document evi-
dence of efficacy,and a recent trial in 100 patients (56) not included
in the meta-analysis, also failed to show any benefit in addition to
conventional therapy. In addition, treatment with this probiotic
without a previous antibiotic treatment appeared to be actually
detrimental, with fewer patients reaching clinical remission (56).
Are probiotics efficacious in maintaining the remission
achieved pharmacologically? Five trials in UC addressed this issue,
showing no advantage of probiotics administration when com-
pared to placebo only (RR 0.89, 95% CI 0.66–1.21). It is, however,
remarkable that the only pediatric trial conducted with VSL#3
(49) showed actually efficacy of the probiotic (RR 0.29, 95% CI
0.10–0.83). This trial included 29 children, with a recent diagno-
sis of mild to moderate UC who received initially prednisone and
mesalazine plus either placebo or VSL#3 for induction, and once
remission had been obtained, they remained on mesalazine plus
either placebo or VSL#3. The patients were evaluated at 1 month,
2 months, 6 months, and 1 year after diagnosis or at the time of
relapse. An endoscopy was additionally performed at the time of
diagnosis and then repeated at 6 months, 12 months, or at the time
of relapse. The study found that not only the remission but also
the relapse rates were better in the patients treated with VSL#3;
furthermore, endoscopic and histological scores were significantly
better in the VSL#3 group than in the placebo group (p< 0.05).
Another pediatric trial, not included in the 2014 meta-analysis,
examined 31 children with mild to moderate ulcerative procti-
tis/proctosigmoiditis (57); they received by enema a solution with
L. reuteri ATCC 55730 or placebo during 8 weeks, in addition to the
oral treatment with mesalazine. A clinical, endoscopic, histologi-
cal, and immune evaluation (IL-10, IL-1b, TNFα, and IL-8) was
performed. Clinical and endoscopic improvements were shown to
be better in the probiotic group, and the histological score was
significantly decreased in the L. reuteri group (p< 0.01). In the
L. reuteri group, a significant increase in the mucosal expression
levels of IL-10 and a significant decrease in the levels of IL-1b,
TNFα, and IL-8 mucosal expression levels (p< 0.01) were also
documented.
CONCLUSIONS ON THE EFFICACY OF PROBIOTICS IN
PEDIATRIC IBS AND IBD
In IBS, some strains of probiotics offer a modest but meaningful
benefit in the treatment of FGID in children, and especially in
the treatment of abdominal pain. Considering their outstanding
safety profile and the scarcity of alternative safe treatment options,
they appear to have an interesting role.
As for IBD, at present there is no evidence of efficacy for any
strain in CD. It must, however, be considered that CD is a very
heterogeneous condition, with varying degrees of genetic compo-
nents, very different phenotypes, and variable degrees of severity.
It is therefore very likely that the patient-probiotic profiles so far
examined are not exhaustive; a better refinement of the strains,
their dosage, and their specific applications to well-identified sub-
groups of patients may yield valuable information and possibly
some useful therapeutic implications. In ulcerative colitis on the
other hand, there is already evidence of efficacy for the probiotic
mixture VSL#3. Further, larger prospective RCTs appear definitely
warranted.
PREBIOTICS IN IBS
Four RCTs have investigated the efficacy of prebiotics to treat IBS
symptoms, all of them in adult patients. The first RCT was a cross-
over trial where 21 patients with IBS were given 6 g/day of FOS
(58). There were no significant deviations in symptoms for the
treated or control group. The second study conducted by Ole-
sen and Gudmand-Hoyer involved 96 patients with IBS who were
given either 20 g/day of FOS or placebo for 12 weeks (59). This high
dose increased symptoms at 4–6 weeks thereby suggesting high
dosage of prebiotics such as FOS would be ineffective and poten-
tially even dangerous for treatment of IBS. The third study involved
105 patients with functional bowel disorders who were adminis-
tered 5 g/day of oligofructose (60). Although improvements in
global symptoms and bloating were noted, only 50 patients could
be included in the final analysis due to withdrawal or violation of
protocol. The latest study was conducted over a period of 4 weeks
and involved random administration of 3.5 g/day of GOS, 7 g/day
of GOS, or placebo to 44 IBS patients (61). The administration
of GOS at both doses resulted in an increased predominance of
bifidobacteria in fecal samples; and the lowest dose also resulted in
significant improvement in bloating, flatulence, and global relief
of IBS symptoms. However, higher dosage of GOS caused worse
bloating symptoms.
Thus, with all the risks involved in drawing conclusions from
only four studies and keeping in mind no data are available so far
in children, it is quite conceivable a low to moderate dose of prebi-
otics might provide some symptom relief, while higher doses may
end up being detrimental. This negative effect may well be related
to increased luminal gas production following fermentation. In
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fact, it has been shown that a diet high in fermentable carbohy-
drates elevated hydrogen gas in 15 patients with IBS and 15 health
control patients (62). This resulted in increased abdominal pain,
bloating, and flatulence among IBS patients as well as flatulence
among healthy controls. To further support this concept, it has
recently been shown that a diet low in fermentable oligosaccha-
rides, disaccharides, monosaccharides, and polyols (FODMAP) is
beneficial in improving IBS symptoms (63), while a diet rich in
these carbohydrates increases fasting colonic volume and breath
hydrogen in healthy volunteers (64).
PREBIOTICS IN IBD
In spite of a substantial amount of promising data obtained in ani-
mal systems (65–68) there are few studies investigating the efficacy
of prebiotics in humans with IBD, and none in children.
An open-label study with FOS supplementation in 10 adult
CD patients (69) showed that FOS improved disease activity
index, increased fecal bifidobacteria concentrations and modified
mucosal dendritic cell function.
A more recent RCT in 103 patients with CD randomized to
receive FOS (n= 54) or placebo (n= 49) failed to show any sig-
nificant difference in the number of patients achieving a clinical
response between the FOS and placebo groups (70).
In an open trial involving patients with mild to moderate UC
who had been unresponsive or intolerant to standard treatment,
patients received 20–30 mg of germinated barley food (GBF) in a
daily feeding (71). At 4 weeks, the GBF treatment had resulted in
clinical and endoscopic improvement regardless of initial extent
of disease, and the improvement was linked to elevated butyrate
concentration in stool. A study by Kanauchi et al. (72) found that
GBF increased levels of Bifidobacterium and Eubacterium limosum
and appeared to prolong remission in UC patients.
Casellas et al. in a placebo-controlled RCT on 19 UC patients
treated with mesalazine showed that the group who received
oligofructose-enriched inulin supplementation had a lower fecal
calprotectin than controls (73).
CONCLUSIONS ON THE EFFICACY OF PREBIOTICS IN
PEDIATRIC IBS AND IBD
Prebiotics in IBS have not been studied in children; hence no
conclusion can obviously be drawn. The tricky dose–effect rela-
tionship found in adult makes their use in children not promising
and probably potentially quite limited.
In IBD, again no data are available in pediatric age. Here,
however, considering some positive effect in the limited stud-
ies available in adults, it would appear that prebiotics may have
some potential. Needless to say, much more evidence needs to
be generated before any meaningful clinical indication can be
identified.
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